Endo International (NASDAQ:
ENDP) and Teva Pharmaceutical Industries (NYSE:
TEVA) are down
11% and
3%, respectively, premarket in sympathy with Mallinckrodt’s
40% plunge in reaction to its plan to restructure in the face of thousands of opioid-related lawsuits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.